A path to translation: How 3D patient tumor avatars enable next generation precision oncology

TY - JOUR

T1 - A path to translation

T2 - How 3D patient tumor avatars enable next generation precision oncology

AU - Barroso, Margarida

AU - Chheda, Milan G

AU - Clevers, Hans

AU - Elez, Elena

AU - Kaochar, Salma

AU - Kopetz, Scott E

AU - Li, Xiao-Nan

AU - Meric-Bernstam, Funda

AU - Meyer, Clifford A

AU - Mou, Haiwei

AU - Naegle, Kristen M

AU - Pera, Martin F

AU - Perova, Zinaida

AU - Politi, Katerina A

AU - Raphael, Benjamin J

AU - Robson, Paul

AU - Sears, Rosalie C

AU - Tabernero, Josep

AU - Tuveson, David A

AU - Welm, Alana L

AU - Welm, Bryan E

AU - Willey, Christopher D

AU - Salnikow, Konstantin

AU - Chuang, Jeffrey H

AU - Shen, Xiling

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/10/18

Y1 - 2022/10/18

N2 - 3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

AB - 3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

U2 - 10.1016/j.ccell.2022.09.017

DO - 10.1016/j.ccell.2022.09.017

M3 - Article

C2 - 36270276

SN - 1535-6108

JO - Cancer Cell

JF - Cancer Cell

ER -